Chemokine-enhanced chemotaxis of lymphangioleiomyomatosis cells with mutations in the tumor suppressor TSC2 gene

Journal of Immunology

Volumn 182, Issue 3, 2009, Pages 1270-1277

  Pacheco Rodriguez, Gustavo ^a   Kumaki, Fumiyuki ^a   Steagall, Wendy K ^a   Zhang, Yi ^a   Ikeda, Yoshihiko ^a   Lin, Jing Ping ^a   Billings, Eric M ^a   Moss, Joel ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CXCL1 CHEMOKINE; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; MONOCYTE CHEMOTACTIC PROTEIN 1; BETA CHEMOKINE; CCL2 PROTEIN, HUMAN; CCL27 PROTEIN, HUMAN; CCL28 PROTEIN, HUMAN; CUTANEOUS T CELL ATTRACTING CHEMOKINE; TUBERIN; TUMOR SUPPRESSOR PROTEIN;

ADULT; ARTICLE; BREAST CANCER; CHEMOTAXIS; CONTROLLED STUDY; FEMALE; GENE; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; LYMPHANGIOLEIOMYOMATOSIS; MELANOMA; METASTASIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; TSC2 GENE; TUMOR CELL; TUMOR SUPPRESSOR GENE; UNINDEXED SEQUENCE; BIOSYNTHESIS; CASE CONTROL STUDY; CELL LINE; DNA MICROARRAY; GENE EXPRESSION PROFILING; GENETIC POLYMORPHISM; GENETICS; IMMUNOLOGY; LUNG; METABOLISM; MIDDLE AGED; NEUTROPHIL CHEMOTAXIS; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ADULT; CASE-CONTROL STUDIES; CELL LINE; CELL LINE, TUMOR; CHEMOKINE CCL2; CHEMOKINE CCL27; CHEMOKINES; CHEMOKINES, CC; CHEMOTAXIS, LEUKOCYTE; FEMALE; GENE EXPRESSION PROFILING; GENES, TUMOR SUPPRESSOR; HUMANS; LUNG; LYMPHANGIOLEIOMYOMATOSIS; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMORPHISM, GENETIC; TUMOR SUPPRESSOR PROTEINS;

EID: 63149180675     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.182.3.1270     Document Type: Article

References (62)

1. Chambers, A. F., A. C. Groom, and I. C. MacDonald. 2002. Dissemination and growth of cancer cells in metastatic sites. Nat. Rev. Cancer 2: 563-572.
2. Paget, S. 1889. The distribution of secondary growths in cancer of the breast. Lancet 1: 571-573.
3. Hujanen, E. S., and V. P. Terranova. 1985. Migration of tumor cells to organ-derived chemoattractants. Cancer Res. 45: 3517-3521.
4. Moore, M. A. 2001. The role of chemoattraction in cancer metastases. Bioessays 23: 674-676.
5. Liotta, L. A., and E. C. Kohn. 2001. The microenvironment of the tumour-host interface. Nature 411: 375-379.
6. Balkwill, F., K. A. Charles, and A. Mantovani. 2005. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cells 7: 211-217.
7. Singer, C. A., S. Salinthone, K. J. Baker, and W. T. Gerthoffer. 2004. Synthesis of immune modulators by smooth muscles. Bioessays 26: 646-655.
8. Muller, A., B. Homey, H. Soto, N. Ge, D. Catron, M. E. Buchanan, T. McClanahan, E. Murphy, W. Yuan, S. N. Wagner, et al. 2001. Involvement of chemokine receptors in breast cancer metastasis. Nature 410: 50-56.
9. Steagall, W. K., A. M. Taveira-DaSilva, and J. Moss. 2005. Clinical and molecular insights into lymphangioleiomyomatosis. Sarcoidosis Vasc. Diffuse Lung Dis. 22(Suppl. 1): S49-S66.
10. Carsillo, T., A. Astrinidis, and E. P. Henske. 2000. Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. Proc. Natl. Acad. Sci. USA 97: 6085-6090.
11. Crino, P. B., K. L. Nathanson, and E. P. Henske. 2006. The tuberous sclerosis complex. N. Engl. J. Med. 355: 1345-1356.
12. Strizheva, G. D., T. Carsillo, W. D. Kruger, E. J. Sullivan, J. H. Ryu, and E. P. Henske. 2001. The spectrum of mutations in TSC1 and TSC2 in women with tuberous sclerosis and lymphangiomyomatosis. Am. J. Respir. Crit. Care Med. 163: 253-258.
13. Sato, T., K. Seyama, T. Kumasaka, H. Fujii, Y. Setoguchi, T. Shirai, Y. Tomino, O. Hino, and Y. Fukuchi. 2004. A patient with TSC1 germline mutation whose clinical phenotype was limited to lymphangioleiomyomatosis. J. Intern. Med. 256: 166-173.
14. Bittmann, I., B. Rolf, G. Amann, and U. Lohrs. 2003. Recurrence of lymphangioleiomyomatosis after single lung transplantation: new insights into pathogenesis. Hum. Pathol. 34: 95-98.
15. Karbowniczek, M., A. Astrinidis, B. R. Balsara, J. R. Testa, J. H. Lium, T. V. Colby, F. X. McCormack, and E. P. Henske. 2003. Recurrent lymphangiomyomatosis after transplantation: genetic analyses reveal a metastatic mechanism. Am. J. Respir. Crit. Care Med. 167: 976-982.
16. Crooks, D. M., G. Pacheco-Rodriguez, R. M. DeCastro, J. P. McCoy, Jr., J. A. Wang, F. Kumaki, T. Darling, and J. Moss. 2004. Molecular and genetic analysis of disseminated neoplastic cells in lymphangioleiomyomatosis. Proc. Natl. Acad. Sci. USA 101: 17462-17467.
17. Bonetti, F., M. Pea, G. Martignoni, G. Zamboni, and P. Iuzzolino. 1991. Cellular heterogeneity in lymphangiomyomatosis of the lung. Hum. Pathol. 22: 727-728.
18. Hoon, V., S. N. Thung, M. Kaneko, and P. D. Unger. 1994. HMB-45 reactivity in renal angiomyolipoma and lymphangioleiomyomatosis. Arch. Pathol. Lab. Med. 118: 732-734.
19. Guinee, D. G., Jr., I. Feuerstein, M. N. Koss, and W. D. Travis. 1994. Pulmonary lymphangioleiomyomatosis: diagnosis based on results of transbronchial biopsy and immunohistochemical studies and correlation with high-resolution computed tomography findings. Arch. Pathol. Lab. Med. 118: 846-849.
20. Adema, G. J., A. J. de Boer, A. M. Vogel, W. A. Loenen, and C. G. Figdor. 1994. Molecular characterization of the melanocyte lineage-specific antigen gp100. J. Biol. Chem. 269: 20126-20133.
21. Matsumoto, Y., K. Horiba, J. Usuki, S. C. Chu, V. J. Ferrans, and J. Moss. 1999. Markers of cell proliferation and expression of melanosomal antigen in lymphangioleiomyomatosis. Am. J. Respir. Cell Mol. Biol. 21: 327-336.
22. Goncharova, E. A., D. A. Goncharov, A. Eszterhas, D. S. Hunter, M. K. Glassberg, R. S. Yeung, C. L. Walker, D. Noonan, D. J. Kwiatkowski, M. M. Chou, et al. 2002. Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation: a role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis (LAM). J. Biol. Chem. 277: 30958-30967.
23. Pacheco-Rodriguez, G., W. K. Steagall, D. M. Crooks, L. A. Stevens, H. Hashimoto, S. Li, J. A. Wang, T. N. Darling, and J. Moss. 2007. TSC2 loss in lymphangioleiomyomatosis cells correlated with expression of CD44v6, a molecular determinant of metastasis. Cancer Res. 67: 10573-10581.
24. Zlotnik, A., and O. Yoshie. 2000. Chemokines: a new classification system and their role in immunity. Immunity 12: 121-127.
25. Bacon, K., M. Baggiolini, H. Broxmeyer, R. Horuk, I. Lindley, A. Mantovani, K. Maysushima, P. Murphy, H. Nomiyama, J. Oppenheim, et al. 2002. Chemokine/chemokine receptor nomenclature. J. Interferon Cytokine Res. 22: 1067-1068.
26. IUIS/WHO Subcommittee on Chemokine Nomenclature. 2003. Chemokine/chemokine receptor nomenclature. Cytokine 21: 48-49.
27. Balkwill, F. 2004. Cancer and the chemokine network. Nat. Rev. Cancer 4: 540-550.
28. Li, S., F. Takeuchi, J. A. Wang, C. Fuller, G. Pacheco-Rodriguez, J. Moss, and T. N. Darling. 2005. MCP-1 overexpressed in tuberous sclerosis lesions acts as a paracrine factor for tumor development. J. Exp. Med. 202: 617-624.
29. Cooper, J. A. 1987. Effects of cytochalasin and phalloidin on actin. J. Cell Biol. 105: 1473-1478.
30. Schliwa, M. 1982. Action of cytochalasin D on cytoskeletal networks. J. Cell Biol. 92: 79-91.
31. Bhowmick, N. A., E. G. Neilson, and H. L. Moses. 2004. Stromal fibroblasts in cancer initiation and progression. Nature 432: 332-337.
32. Li, Q., S. Withoff, and I. M. Verma. 2005. Inflammation-associated cancer: NF-κB is the lynchpin. Trends Immunol. 26: 318-325.
33. Ferrans, V. J., Z. X. Yu, W. K. Nelson, J. C. Valencia, A. Tatsuguchi, N. A. Avila, W. Riemenschn, K. Matsui, W. D. Travis, and J. Moss. 2000. Lymphangioleiomyomatosis (LAM): a review of clinical and morphological features. J. Nippon Med. Sch. 67: 311-329.
34. Ding, M., S. Cui, C. Li, S. Jothy, V. Haase, B. M. Steer, P. A. Marsden, J. Pippin, S. Shankland, M. P. Rastaldi, et al. 2006. Loss of the tumor suppressor Vhlh leads to upregulation of Cxcr4 and rapidly progressive glomerulonephritis in mice. Nat. Med. 12: 1081-1087.
35. Ceradini, D. J., and G. C. Gurtner. 2005. Homing to hypoxia: HIF-1 as a mediator of progenitor cell recruitment to injured tissue. Trends Cardiovasc. Med. 15: 57-63.
36. Taveira-DaSilva, A. M., M. P. Stylianou, C. J. Hedin, A. S. Kristof, N. A. Avila, A. Rabel, W. D. Travis, and J. Moss. 2003. Maximal oxygen uptake and severity of disease in lymphangioleiomyomatosis. Am. J. Respir. Crit. Care Med. 168: 1427-1431.
37. Semenza, G. L. 2003. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 3: 721-732.
38. Brugarolas, J. B., F. Vazquez, A. Reddy, W. R. Sellers, and W. G. Kaelin, Jr. 2003. TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell 4: 147-158.
39. Pan, J., J. Mestas, M. D. Burdick, R. J. Phillips, G. V. Thomas, K. Reckamp, J. A. Belperio, and R. M. Strieter. 2006. Stromal derived factor-1 (SDF-1/CXCL12) and CXCR4 in renal cell carcinoma metastasis. Mol. Cancer 5: 56.
40. Ceradini, D. J., A. R. Kulkarni, M. J. Callaghan, O. M. Tepper, N. Bastidas, M. E. Kleinman, J. M. Capla, R. D. Galiano, J. P. Levine, and G. C. Gurtner. 2004. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat. Med. 10: 858-864.
41. Taniguchi, T., K. Ogasawara, A. Takaoka, and N. Tanaka. 2001. IRF family of transcription factors as regulators of host defense. Annu. Rev. Immunol. 19: 623-655.
42. LaVoie, H. A. 2003. The role of GATA in mammalian reproduction. Exp. Biol. Med. 228: 1282-1290.
43. Kruger, B., B. Schroppel, R. Ashkan, B. Marder, C. Zulke, B. Murphy, B. K. Kramer, and M. Fischereder. 2002. A monocyte chemoattractant protein-1 (MCP-1) polymorphism and outcome after renal transplantation. J. Am. Soc. Nephrol. 13: 2585-2589.
44. Rovin, B. H., L. Lu, and R. Saxena. 1999. A novel polymorphism in the MCP-1 gene regulatory region that influences MCP-1 expression. Biochem. Biophys. Res. Commun. 259: 344-348.
45. Simeoni, E., M. M. Hoffmann, B. R. Winkelmann, J. Ruiz, S. Fleury, B. O. Boehm, W. Marz, and G. Vassalli. 2004. Association between the A-2518G polymorphism in the monocyte chemoattractant protein-1 gene and insulin resistance and type 2 diabetes mellitus. Diabetologia 47: 1574-1580.
46. Keszei, M., A. Nagy, G. T. Kozma, K. Radosits, G. Tolgyesi, A. Falus, and C. Szalai. 2006. Pediatric asthmatic patients have low serum levels of monocyte chemoattractant protein-1. J. Asthma 43: 399-404.
47. Hwang, S. Y., M. L. Cho, B. Park, J. Y. Kim, Y. H. Kim, D. J. Min, J. K. Min, and H. Y. Kim. 2002. Allelic frequency of the MCP-1 promoter -2518 polymorphism in the Korean population and in Korean patients with rheumatoid arthritis, systemic lupus erythematosus and adult-onset Still's disease. Eur. J. Immunogenet. 29: 413-416.
48. Govindarajan, B., D. J. Brat, M. Csete, W. D. Martin, E. Murad, K. Litani, C. Cohen, F. Cerimele, M. Nunnelley, B. Lefkove, et al. 2005. Transgenic expression of dominant negative tuberin through a strong constitutive promoter results in a tissue-specific tuberous sclerosis phenotype in the skin and brain. J. Biol. Chem. 280: 5870-5874.
49. Minn, A. J., G. P. Gupta, P. M. Siegel, P. D. Bos, W. Shu, D. D. Giri, A. Viale, A. B. Olshen, W. L. Gerald, and J. Massague. 2005. Genes that mediate breast cancer metastasis to lung. Nature 436: 518-524.
50. Yang, G., D. G. Rosen, Z. Zhang, R. C. Bast, Jr., G. B. Mills, J. A. Colacino, I. Mercado-Uribe, and J. Liu. 2006. The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis. Proc. Natl. Acad. Sci. USA 103: 16472-16477.
51. Matsui, K., K. Riemenschneider, W. S. L. Hilbert, Z. X. Yu, K. Takeda, W. D. Travis, J. Moss, and V. J. Ferrans. 2000. Hyperplasia of type II pneumocytes in pulmonary lymphangioleiomyomatosis. Arch. Pathol. Lab. Med. 124: 1642-1648.
52. Taveira-DaSilva, A. M., C. Hedin, M. P. Stylianou, W. D. Travis, K. Matsui, V. J. Ferrans, and J. Moss. 2001. Reversible airflow obstruction, proliferation of abnormal smooth muscle cells, and impairment of gas exchange as predictors of outcome in lymphangioleiomyomatosis. Am. J. Respir. Crit. Care Med. 164: 1072-1076.
53. Ryu, J. H., J. L. Myers, and S. J. Swensen. 2003. Bronchiolar disorders. Am. J. Respir. Crit. Care Med. 168: 1277-1292.
54. Henske, E. P. 2003. Metastasis of benign tumor cells in tuberous sclerosis complex. Genes Chromosomes Cancer 38: 376-381.
55. Murakami, T., A. R. Cardones, S. E. Finkelstein, N. P. Restifo, B. A. Klaunberg, F. O. Nestle, S. S. Castillo, P. A. Dennis, and S. T. Hwang. 2003. Immune evasion by murine melanoma mediated through CC chemokine receptor-10. J. Exp. Med. 198: 1337-1347.
56. Murakami, T., A. R. Cardones, and S. T. Hwang. 2004. Chemokine receptors and melanoma metastasis. J. Dermatol. Sci. 36: 71-78.
57. Schecter, A. D., T. M. Calderon, A. B. Berman, C. M. McManus, J. T. Fallon, M. Rossikhina, W. Zhao, G. Christ, J. W. Berman, and M. B. Taubman. 2000. Human vascular smooth muscle cells possess functional CCR5. J. Biol. Chem. 275: 5466-5471.
58. Schecter, A. D., A. B. Berman, L. Yi, A. Mosoian, C. M. McManus, J. W. Berman, M. E. Klotman, and M. B. Taubman. 2001. HIV envelope gp120 activates human arterial smooth muscle cells. Proc. Natl. Acad. Sci. USA 98: 10142-10147.
59. Lucas, A. D., C. Bursill, T. J. Guzik, J. Sadowski, K. M. Channon, and D. R. Greaves. 2003. Smooth muscle cells in human atherosclerotic plaques express the fractalkine receptor CX3CR1 and undergo chemotaxis to the CX3C chemokine fractalkine (CX3CL1). Circulation 108: 2498-2504.
60. Murray, L. A., F. Syed, L. Li, D. E. Griswold, and A. M. Das. 2006. Role of chemokines in severe asthma. Curr. Drug Targets 7: 579-588.
61. Lengauer, C., K. W. Kinzler, and B. Vogelstein. 1998. Genetic instabilities in human cancers. Nature 396: 643-649.
62. Devilee, P., A. M. Cleton-Jansen, and C. J. Cornelisse. 2001. Ever since Knudson. Trends Genet. 17: 569-573.